A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Mar 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRLBF SEC filings page.
CRESCO LABS INC (CRLBF) reported $655.8M in revenue for fiscal year 2025, down 9.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cresco’s reported recovery in FY2024 reversed in FY2025, while positive cash generation persists despite recurring net losses.
Assets fell12.0% from FY2023 to FY2025 while liabilities were broadly stable, so the balance sheet contracted without a matching reduction in obligations. Equity reached$340M and debt-to-equity 1.2x in FY2025 even though long-term debt declined, indicating leverage rose mainly because the equity base eroded.
FY2025 still produced positive free cash flow of
Gross margin stability did not translate into stable operating earnings: operating margin moved from
Financial Health Signals
CRESCO LABS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
CRESCO LABS INC scores -0.98, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($220.1M) relative to total liabilities ($944.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CRESCO LABS INC passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
CRESCO LABS INC reported a net loss of $135.4M while generating $72.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
CRESCO LABS INC reported an operating loss of $28.0M against $41.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
CRESCO LABS INC held $57.9M in cash against $417.1M in long-term debt as of Q4 2025.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
CRLBF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
CRLBF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2540-F | Q4'2440-F | Q4'2310-K |
|---|---|---|---|
| Total Assets | $1.2B-11.7% | $1.4B-0.2% | $1.4B |
| Current Assets | $259.3M-11.9% | $294.3M+5.8% | $278.1M |
| Cash & Equivalents | $57.9M-57.9% | $137.6M+33.0% | $103.4M |
| Short-Term Investments | $0 | $0 | $0 |
| Inventory | $98.7M+18.4% | $83.3M-22.7% | $107.8M |
| Accounts Receivable | $37.9M-26.5% | $51.6M+1.0% | $51.1M |
| Long-Term Investments | $0 | $0 | $0 |
| Goodwill | $208.2M-26.6% | $283.5M+1.4% | $279.7M |
| Total Liabilities | $944.8M-2.3% | $967.2M+4.0% | $930.4M |
| Current Liabilities | $100.2M+6.2% | $94.3M-52.9% | $200.2M |
| Non-Current Liabilities | $844.6M-3.2% | $872.8M+19.5% | $730.2M |
| Long-Term Debt | $417.1M-9.5% | $460.8M-7.4% | $497.7M |
| Total Equity | $340.4M-28.3% | $474.9M-6.1% | $505.7M |
| Retained Earnings | -$1.5B-10.9% | -$1.4B-6.9% | -$1.3B |
CRLBF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
CRLBF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CRESCO LABS INC CRLBF | FY2025 | $655.8M | -$135.4M | -20.6% | $220.1M | — |
| VERANO HLDGS CORP VRNOF | FY2025 | $821.5M | -$258K | 0.0% | $476.1M | — |
| VIREO GROWTH INC VREOF | FY2025 | $268.8M | -$68.1M | -25.3% | $470.8M | — |
| GLASS HOUSE BRANDS INC GLASF | FY2025 | $182.0M | -$29.7M | -16.3% | $1.1B | — |
| NIKA PHARMACEUTICALS INC NIKA | FY2025 | N/A | -$76K | N/A | $429.9M | — |
| ELITE PHARMS INC ELTP | FY2026 | $148.9M | $44.9M | 30.1% | $273.9M | — |
Where CRESCO LABS INC Ranks
Frequently Asked Questions
What is CRESCO LABS INC's annual revenue?
CRESCO LABS INC (CRLBF) reported $655.8M in total revenue for fiscal year 2025. This represents a -9.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CRESCO LABS INC's revenue growing?
CRESCO LABS INC (CRLBF) revenue declined by 9.5% year-over-year, from $724.3M to $655.8M in fiscal year 2025.
Is CRESCO LABS INC profitable?
No, CRESCO LABS INC (CRLBF) reported a net income of -$135.4M in fiscal year 2025, with a net profit margin of -20.6%.
What is CRESCO LABS INC's EBITDA?
CRESCO LABS INC (CRLBF) had EBITDA of $20.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does CRESCO LABS INC have?
As of fiscal year 2025, CRESCO LABS INC (CRLBF) had $57.9M in cash and equivalents against $417.1M in long-term debt.
What is CRESCO LABS INC's gross margin?
CRESCO LABS INC (CRLBF) had a gross margin of 49.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is CRESCO LABS INC's operating margin?
CRESCO LABS INC (CRLBF) had an operating margin of -4.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is CRESCO LABS INC's net profit margin?
CRESCO LABS INC (CRLBF) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is CRESCO LABS INC's return on equity (ROE)?
CRESCO LABS INC (CRLBF) has a return on equity of -39.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CRESCO LABS INC's free cash flow?
CRESCO LABS INC (CRLBF) generated $37.8M in free cash flow during fiscal year 2025. This represents a -66.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CRESCO LABS INC's operating cash flow?
CRESCO LABS INC (CRLBF) generated $72.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are CRESCO LABS INC's total assets?
CRESCO LABS INC (CRLBF) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are CRESCO LABS INC's capital expenditures?
CRESCO LABS INC (CRLBF) invested $35.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is CRESCO LABS INC's current ratio?
CRESCO LABS INC (CRLBF) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.
What is CRESCO LABS INC's debt-to-equity ratio?
CRESCO LABS INC (CRLBF) had a debt-to-equity ratio of 1.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CRESCO LABS INC's return on assets (ROA)?
CRESCO LABS INC (CRLBF) had a return on assets of -11.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CRESCO LABS INC's P/E ratio?
CRESCO LABS INC (CRLBF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $220.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CRESCO LABS INC's price-to-sales ratio?
CRESCO LABS INC (CRLBF) trades at 0.3x sales, its market capitalization divided by revenue of $655.8M revenue, FY2025. The market capitalization is $220.1M as of Oct 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CRESCO LABS INC's Altman Z-Score?
CRESCO LABS INC (CRLBF) has an Altman Z-Score of -0.98, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CRESCO LABS INC's Piotroski F-Score?
CRESCO LABS INC (CRLBF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CRESCO LABS INC's earnings high quality?
CRESCO LABS INC (CRLBF) reported a net loss of $135.4M while generating $72.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CRESCO LABS INC cover its interest payments?
CRESCO LABS INC (CRLBF) reported an operating loss of $28.0M against $41.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.